Lanadelumab 300mg/2ml solution for injection pre-filled syringes
NHS hospitals in England used £28,982,070 of indicative cost of Lanadelumab 300mg/2ml solution for injection pre-filled syringes in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 16.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Lanadelumab 300mg/2ml solution for injection pre-filled syringes: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Lanadelumab 300mg/2ml solution for injection pre-filled syringes most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University Hospital Southampton Nhs Ft | £3,092,580 |
| Cambridge Univ Hosp Nhs Foundation Trust | £3,080,160 |
| Univ Hpl B/Ham Nhs Foundation Trust | £3,067,740 |
| North Bristol Nhs Trust | £2,446,740 |
| University Hospitals Plymouth Nhs Trust | £2,409,480 |
| Sheffield Teaching Hospitals Nhs Trust | £2,036,880 |
| Frimley Health Nhs Foundation Trust | £1,850,580 |
| Oxford University Hospitals Nhs Ft | £1,664,280 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,552,500 |
| Nottingham University Hospitals Trust | £1,229,580 |
The primary-care picture
Lanadelumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Lanadelumab medicine page.